EQRX Stock Overview
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
EQRx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.34 |
| 52 Week High | US$3.96 |
| 52 Week Low | US$1.58 |
| Beta | 0.48 |
| 1 Month Change | 5.41% |
| 3 Month Change | 4.46% |
| 1 Year Change | -36.24% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.79% |
Recent News & Updates
Recent updates
We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely
Jul 25
EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Feb 22We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate
Nov 08EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs
Aug 28 EQRx GAAP EPS of -$0.17 beats by $0.03
Aug 11Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation
Jul 24We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth
Apr 08EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans
Dec 24Shareholder Returns
| EQRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.3% | -2.7% | -2.6% |
| 1Y | -36.2% | -6.2% | 23.1% |
Return vs Industry: EQRX underperformed the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: EQRX underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| EQRX volatility | |
|---|---|
| EQRX Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EQRX has not had significant price volatility in the past 3 months.
Volatility Over Time: EQRX's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 362 | Melanie Nallicheri | www.eqrx.com |
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company’s clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis.
EQRx, Inc. Fundamentals Summary
| EQRX fundamental statistics | |
|---|---|
| Market cap | US$1.14b |
| Earnings (TTM) | -US$260.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.4x
P/E RatioIs EQRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EQRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$260.32m |
| Earnings | -US$260.31m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EQRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/10 08:53 |
| End of Day Share Price | 2023/11/08 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EQRx, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Shibutani | Goldman Sachs |
| Akash Tewari | Jefferies LLC |
| Christopher Schott | J.P. Morgan |